Biomea Fusion Inc (BMEA) Stock Price, Quote & News

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, whic...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 980 9099

Website: biomeafusion.com

Address:

1599 Industrial Road, San Carlos, United States

monstertrades1 Aug. 4 at 5:39 PM

$BMEA Price Target Breakdown Average Target: ~$7.38 across consensus trackers, suggesting a potential upside of over 500% from its recent trading price near $1.17–$1.25. High Forecast: $10.00 to $12.00 depending on the specific group of covering Wall Street analysts. Low Forecast: $4.00. https://www.zacks.com/stock/research/BMEA/price-target-stock-forecast

0 · Reply

monstertrades1 Aug. 4 at 5:32 PM

$BMEA my thoughts on obesity trial: A.) Safety = excellent so far B.) Efficacy = great, which explains why they noted that positive observations were "emerging." Now the question becomes how much weight loss in %. I predict 6.5% on the conservative side. "Based on the favorable safety and tolerability profile observed to date, along with emerging pharmacokinetic and clinical observations, we elected to add an additional MAD cohort to evaluate a rapid one-step titration and further optimize the weight reduction potential of BMF-650." $SPY $QQQ

1 · Reply

monstertrades1 Aug. 4 at 5:14 PM

$BMEA

0 · Reply

monstertrades1 Aug. 4 at 5:14 PM

$BMEA

0 · Reply

Hakari34 Aug. 4 at 4:22 PM

$BMEA Funn couple weeks are ahead. Its that sudden surge of humidity before a summer storm you can smell it.

0 · Reply

monstertrades1 Aug. 4 at 3:09 PM

$BMEA bullish !

0 · Reply

monstertrades1 Aug. 3 at 8:46 PM

$BMEA move your proceeds from $PLTR over to $BMEA lots of data readout in obesity and diabetes fields. Very bullish!

0 · Reply

Philarney Aug. 3 at 8:25 PM

$BMEA Big institutional vote of confidence! 🚨 According to the latest 13F SEC filing dated July 23, 2026, Fideuram - Intesa Sanpaolo Private Banking S.p.a. increased its position in Biomea Fusion by +29.83%, bringing its total holdings to 723,176 shares! Who is Fideuram? 🏛️ • Private banking & wealth management powerhouse of Intesa Sanpaolo Group (Italy’s top bank & one of Europe's premier wealth managers with €350B+ AUM). • A major European institution known for high-conviction, long-term stock picking. When smart money of this scale aggressively expands its stake while shorts are actively covering, it speaks volumes. 📈🚀

4 · Reply

Philarney Aug. 3 at 8:16 PM

$BMEA BMEA Official Short Interest down 24.4% !!! • June 30: 13.83M shares short (20.52% of float) • July 15: 10.45M shares short (15.50% of float) 📉 -24.4% drop in shorted shares (-3.38M shares covered)! The selling pressure is fading fast. Let's be logical: if current developments were negative, shorts would be doubling down and hammering the stock lower. Instead, they are covering and stepping back. The next official FINRA short interest data (settlement date July 31) will be released in just a few days on August 11—expecting this trend to continue as the tide turns in favor of the bulls. 🚀

2 · Reply

monstertrades1 Aug. 3 at 7:58 PM

$BMEA https://tradersunion.com/news/business-wealth/show/2864380-icovamenib-diabetes-trial/

0 · Reply

Biomea Fusion Transcript: AGM 2026

Jun 5, 2026, 7:32 PM EDT - 2 months ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

2026-06-04T19:41:19.000Z - 2 months ago

Biomea Fusion management to meet with Citizens

Jun 4, 2026, 8:10 AM EDT - 2 months ago

Biomea Fusion Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T14:46:35.000Z - 2 months ago

Biomea Fusion partners with University of Leicester on obesity study

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

May 29, 2026, 7:00 AM EDT - 2 months ago

Biomea Fusion Slides: Corporate presentation

May 19, 2026, 3:00 PM EDT - 2 months ago

Biomea Fusion Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 4:05 PM EDT - 3 months ago

Biomea Fusion to Participate at Upcoming Investor Conferences

2026-05-11T23:09:08.000Z - 3 months ago

Biomea Fusion reports Q1 EPS (17c), consensus (19c)

May 11, 2026, 4:54 PM EDT - 3 months ago

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

May 11, 2026, 7:00 AM EDT - 3 months ago

Biomea Fusion Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Biomea Fusion Earnings release: Q1 2026

May 5, 2026, 5:50 PM EDT - 3 months ago

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

May 5, 2026, 2:30 PM EDT - 3 months ago

Biomea Fusion Transcript: Status update

2026-05-05T08:25:12.000Z - 3 months ago

Biomea Fusion initiated with an Outperform at Citizens

Apr 28, 2026, 8:30 AM EDT - 3 months ago

Biomea Fusion Transcript: Study result

Apr 28, 2026, 8:30 AM EDT - 3 months ago

Biomea Fusion Press release: Study result

Apr 28, 2026, 8:30 AM EDT - 3 months ago

Biomea Fusion Slides: Study result

2026-04-27T21:40:11.000Z - 3 months ago

Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial

Apr 27, 2026, 5:37 PM EDT - 3 months ago

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Biomea Fusion Proxy statement: Proxy filing

Apr 21, 2026, 7:00 AM EDT - 3 months ago

Biomea Fusion Slides: Corporate presentation

2026-03-31T11:24:55.000Z - 4 months ago

Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials

Mar 31, 2026, 7:00 AM EDT - 4 months ago

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Mar 30, 2026, 3:00 PM EDT - 4 months ago

Biomea Fusion Transcript: Fireside chat

Mar 30, 2026, 1:00 PM EDT - 4 months ago

Biomea Fusion Transcript: Fireside chat

2026-03-27T10:32:33.000Z - 4 months ago

Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’

Mar 24, 2026, 4:05 PM EDT - 4 months ago

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Mar 24, 2026, 4:00 PM EDT - 4 months ago

Biomea Fusion Annual report: Q4 2025

Mar 24, 2026, 4:00 PM EDT - 4 months ago

Biomea Fusion Earnings release: Q4 2025

2026-03-15T14:50:06.000Z - 5 months ago

Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes

Mar 14, 2026, 4:30 AM EDT - 5 months ago

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

Mar 10, 2026, 2:50 PM EDT - 5 months ago

Biomea Fusion Transcript: The Citizens Life Sciences Conference 2026

2026-03-04T15:46:54.000Z - 5 months ago

Biomea Fusion management to meet virtually with Craig-Hallum

Feb 26, 2026, 10:00 AM EST - 5 months ago

Biomea Fusion Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 10:00 AM EST - 5 months ago

Biomea Fusion Slides: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 24, 2026, 7:00 AM EST - 5 months ago

Biomea Fusion Slides: Corporate presentation

Jan 14, 2026, 8:15 PM EST - 7 months ago

Biomea Fusion Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 7 months ago

Biomea Fusion Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-13T20:20:23.000Z - 7 months ago

Biomea Fusion initiated with a Buy at Rodman & Renshaw

2026-01-12T13:40:46.000Z - 7 months ago

Biomea Fusion enters 2026 focused on icovamenib, BMF-650 milestones

Jan 12, 2026, 8:00 AM EST - 7 months ago

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Jan 12, 2026, 7:00 AM EST - 7 months ago

Biomea Fusion Slides: Corporate presentation

Dec 17, 2025, 7:00 AM EST - 8 months ago

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-10T01:05:10.000Z - 8 months ago

Biomea Fusion announces KOL presentation

Dec 9, 2025, 6:35 PM EST - 8 months ago

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

2025-12-05T12:10:07.000Z - 8 months ago

Biomea Fusion presents COVALENT-111 study results at WCIRDC

Dec 5, 2025, 7:00 AM EST - 8 months ago

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 3, 2025, 7:30 AM EST - 8 months ago

Biomea Fusion Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 8 months ago

Biomea Fusion Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 4:10 PM EST - 8 months ago

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 1, 2025, 4:05 PM EST - 8 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 18, 2025, 7:00 AM EST - 9 months ago

Biomea Fusion Slides: Corporate Presentation

Nov 17, 2025, 11:30 AM EST - 9 months ago

Biomea Fusion Transcript: Jefferies London Healthcare Conference 2025

2025-11-15T15:15:11.000Z - 9 months ago

Biomea Fusion downgraded to Underweight from Neutral at JPMorgan

Nov 10, 2025, 7:00 AM EST - 9 months ago

Biomea Fusion to Participate at Jefferies London Healthcare Conference

2025-11-10T11:35:48.000Z - 9 months ago

Biomea Fusion price target lowered to $6 from $7 at Citi

2025-11-05T12:41:37.000Z - 9 months ago

Biomea Fusion announces presentation of two posters for BMF-650, icovamenib

2025-11-05T12:20:51.000Z - 9 months ago

Biomea Fusion price target lowered to $12 from $16 at D. Boral Capital

Nov 5, 2025, 7:00 AM EST - 9 months ago

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Nov 4, 2025, 4:05 PM EST - 9 months ago

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 4, 2025, 4:00 PM EST - 9 months ago

Biomea Fusion Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 9 months ago

Biomea Fusion Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Oct 23, 2025, 11:00 AM EDT - 10 months ago

Biomea Fusion Transcript: Citi's 2025 SMID Cap Biopharma Call Series

Oct 21, 2025, 7:05 PM EDT - 10 months ago

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Oct 7, 2025, 8:30 AM EDT - 10 months ago

Biomea Fusion Transcript: Study Result

Oct 7, 2025, 8:30 AM EDT - 10 months ago

Biomea Fusion Press release: Study Result

Oct 7, 2025, 8:30 AM EDT - 10 months ago

Biomea Fusion Slides: Study Result

Oct 7, 2025, 8:00 AM EDT - 10 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 10 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:03 PM EDT - 10 months ago

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Oct 1, 2025, 7:00 AM EDT - 10 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2025, 7:00 AM EDT - 11 months ago

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Registration statement: Registration Filing

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Quarterly report: Q2 2025

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jun 23, 2025, 11:00 AM EDT - 1 year ago

Biomea Fusion Slides: Investor Presentation

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 6:28 AM EDT - 1 year ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 17, 2025, 7:28 PM EDT - 1 year ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

$Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025$

Jun 13, 2025, 6:45 AM EDT - 1 year ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

$Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia$

May 14, 2025, 4:05 PM EDT - 1 year ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 5, 2025, 4:05 PM EDT - 1 year ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

May 5, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Quarterly report: Q1 2025

May 5, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Proxy statement: Proxy Filing

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:10 PM EDT - 1 year ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Annual report: Q4 2024

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Earnings release: Q4 2024

Mar 25, 2025, 7:00 PM EDT - 1 year ago

Biomea Fusion Announces Leadership Transition

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 19, 2025, 1:00 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update

Mar 13, 2025, 10:00 AM EDT - 1 year ago

Biomea Fusion Transcript: Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Feb 12, 2025, 10:40 AM EST - 1 year ago

Biomea Fusion Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Jan 15, 2025, 4:30 PM EST - 1 year ago

Biomea Fusion Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 4:30 PM EST - 1 year ago

Biomea Fusion Slides: FY 2025

Dec 17, 2024, 8:10 AM EST - 1 year ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Transcript: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Press release: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Slides: Study Result

Dec 16, 2024, 6:15 PM EST - 1 year ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 12, 2024, 5:02 PM EST - 1 year ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Transcript: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Press release: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Slides: Study Update

$Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia$

Dec 9, 2024, 4:01 PM EST - 1 year ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

$Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia$

Dec 6, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Dec 5, 2024, 7:55 AM EST - 1 year ago

Biomea Fusion Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

Biomea Fusion Transcript: Piper Sandler 36th Annual Healthcare Conference

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Biomea Fusion Press release: Status Update

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Biomea Fusion Slides: Status Update

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

monstertrades1 Aug. 4 at 5:39 PM

0 · Reply

monstertrades1 Aug. 4 at 5:32 PM

1 · Reply

monstertrades1 Aug. 4 at 5:14 PM

$BMEA

0 · Reply

monstertrades1 Aug. 4 at 5:14 PM

$BMEA

0 · Reply

Hakari34 Aug. 4 at 4:22 PM

$BMEA Funn couple weeks are ahead. Its that sudden surge of humidity before a summer storm you can smell it.

0 · Reply

monstertrades1 Aug. 4 at 3:09 PM

$BMEA bullish !

0 · Reply

monstertrades1 Aug. 3 at 8:46 PM

$BMEA move your proceeds from $PLTR over to $BMEA lots of data readout in obesity and diabetes fields. Very bullish!

0 · Reply

Philarney Aug. 3 at 8:25 PM

4 · Reply

Philarney Aug. 3 at 8:16 PM

2 · Reply

monstertrades1 Aug. 3 at 7:58 PM

$BMEA https://tradersunion.com/news/business-wealth/show/2864380-icovamenib-diabetes-trial/

0 · Reply

monstertrades1 Aug. 3 at 7:54 PM

$BMEA excellent investor presentation. There is already a date for phase 2 obesity trial. This translates into something meaningful. Data = good then discuss timing for phase 2.

0 · Reply

HUNTER40 Aug. 3 at 7:26 PM

$BMEA the lady’s in the room are short. Take a message from tales from the crypt the hitch hiker episode from 1991. Repeat after me: thanks for the ride lady thanks for the ride in advance of the results.

0 · Reply

monstertrades1 Aug. 3 at 5:26 PM

$BMEA strong buy 💪 @topstockalerts excellent pick!

0 · Reply

HUNTER40 Aug. 3 at 3:43 PM

$BMEA the stock below $2 is cheap for what the science is, I wouldn’t say pointless uptrend for no reason. I’d say down hear for no reason.

0 · Reply

Hakari34 Aug. 3 at 3:12 PM

$BMEA pointless uptrend for no fucking reason? Thats my boy.

0 · Reply

oldmanrizzer Aug. 3 at 3:07 PM

$BMEA VOLUME!!! I'm glad I shame the market into buying shares. ;)

0 · Reply

Ed202020 Aug. 3 at 3:05 PM

$BMEA added 20,000 shares at 1.20

0 · Reply

HUNTER40 Aug. 3 at 1:56 PM

$BMEA just ripping some one off and snagging 1.15-1.16

1 · Reply

monstertrades1 Aug. 3 at 1:55 PM

$BMEA https://x.com/i/status/2083289640333640109

0 · Reply

monstertrades1 Aug. 3 at 1:45 PM

$BMEA strong buy!

0 · Reply

oldmanrizzer Aug. 3 at 1:34 PM

$BMEA Just keeps getting worse.

1 · Reply

B34Rhunter Aug. 3 at 12:06 PM

$BMEA 8 weeks left in Q3… 650 coming soon 🚀

1 · Reply

Market Cap	84.59M
Revenue (ttm)	0.00
Net Income (ttm)	-61.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	622,512
Avg Vol	875,666
Day's Range	N/A - N/A
Shares Out	72.30M
Stochastic %K	37%
Beta	-0.31
Analysts	Strong Sell
Price Target	$7.29